BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 31872779)

  • 1. Characterizing the Safety Profile of Apixaban Versus Warfarin in Moderate to Severe Chronic Kidney Disease at a Veterans Affairs Hospital.
    Herndon K; Guidry TJ; Wassell K; Elliott W
    Ann Pharmacother; 2020 Jun; 54(6):554-560. PubMed ID: 31872779
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety and Efficacy of Apixaban Versus Warfarin in Patients With Advanced Chronic Kidney Disease.
    Schafer JH; Casey AL; Dupre KA; Staubes BA
    Ann Pharmacother; 2018 Nov; 52(11):1078-1084. PubMed ID: 29871510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the Safety and Effectiveness of Apixaban versus Warfarin in Patients with Severe Renal Impairment.
    Stanton BE; Barasch NS; Tellor KB
    Pharmacotherapy; 2017 Apr; 37(4):412-419. PubMed ID: 28117916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety Outcomes of Apixaban Compared With Warfarin in Patients With End-Stage Renal Disease.
    Sarratt SC; Nesbit R; Moye R
    Ann Pharmacother; 2017 Jun; 51(6):445-450. PubMed ID: 28478715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
    Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH
    Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease.
    Stanifer JW; Pokorney SD; Chertow GM; Hohnloser SH; Wojdyla DM; Garonzik S; Byon W; Hijazi Z; Lopes RD; Alexander JH; Wallentin L; Granger CB
    Circulation; 2020 Apr; 141(17):1384-1392. PubMed ID: 32160801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes.
    Hylek EM; Held C; Alexander JH; Lopes RD; De Caterina R; Wojdyla DM; Huber K; Jansky P; Steg PG; Hanna M; Thomas L; Wallentin L; Granger CB
    J Am Coll Cardiol; 2014 May; 63(20):2141-2147. PubMed ID: 24657685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bleeding rates of Veterans taking apixaban or rivaroxaban for atrial fibrillation or venous thromboembolism.
    Howe Z; Naville-Cook C; Cole D
    J Thromb Thrombolysis; 2019 Feb; 47(2):280-286. PubMed ID: 30449001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin.
    Brekelmans MP; Scheres LJ; Bleker SM; Hutten BA; Timmermans A; Büller HR; Middeldorp S
    Thromb Haemost; 2017 Apr; 117(4):809-815. PubMed ID: 28180233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of apixaban compared to warfarin in hemodialysis patients: Do antiplatelets make a difference?
    Ionescu F; Cooper C; Petrescu I; George J; Mansuri S
    Eur J Haematol; 2021 May; 106(5):689-696. PubMed ID: 33569825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Type of Oral Anticoagulant Dispensed With Adverse Clinical Outcomes in Patients Extending Anticoagulation Therapy Beyond 90 Days After Hospitalization for Venous Thromboembolism.
    Pawar A; Gagne JJ; Gopalakrishnan C; Iyer G; Tesfaye H; Brill G; Chin K; Bykov K
    JAMA; 2022 Mar; 327(11):1051-1060. PubMed ID: 35289881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight.
    Hohnloser SH; Fudim M; Alexander JH; Wojdyla DM; Ezekowitz JA; Hanna M; Atar D; Hijazi Z; Bahit MC; Al-Khatib SM; Lopez-Sendon JL; Wallentin L; Granger CB; Lopes RD
    Circulation; 2019 May; 139(20):2292-2300. PubMed ID: 30773022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apixaban versus Warfarin for the Prevention of Periprocedural Cerebral Thromboembolism in Atrial Fibrillation Ablation: Multicenter Prospective Randomized Study.
    Kuwahara T; Abe M; Yamaki M; Fujieda H; Abe Y; Hashimoto K; Ishiba M; Sakai H; Hishikari K; Takigawa M; Okubo K; Takagi K; Tanaka Y; Nakajima J; Takahashi A
    J Cardiovasc Electrophysiol; 2016 May; 27(5):549-54. PubMed ID: 26766541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral apixaban for the treatment of acute venous thromboembolism.
    Agnelli G; Buller HR; Cohen A; Curto M; Gallus AS; Johnson M; Masiukiewicz U; Pak R; Thompson J; Raskob GE; Weitz JI;
    N Engl J Med; 2013 Aug; 369(9):799-808. PubMed ID: 23808982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effectiveness and safety of apixaban versus warfarin in patients with venous thromboembolism.
    Dawwas GK; Smith SM; Dietrich E; Lo-Ciganic WH; Park H
    Am J Health Syst Pharm; 2020 Jan; 77(3):188-195. PubMed ID: 31974557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial.
    Garcia DA; Wallentin L; Lopes RD; Thomas L; Alexander JH; Hylek EM; Ansell J; Hanna M; Lanas F; Flaker G; Commerford P; Xavier D; Vinereanu D; Yang H; Granger CB
    Am Heart J; 2013 Sep; 166(3):549-58. PubMed ID: 24016506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and Safety of Apixaban versus Warfarin in Venous Thromboembolism Patients with Chronic Kidney Disease.
    Cohen AT; Sah J; Dhamane AD; Lee T; Rosenblatt L; Hlavacek P; Emir B; Delinger R; Yuce H; Luo X
    Thromb Haemost; 2022 Jun; 122(6):926-938. PubMed ID: 34963185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative Clinical and Economic Outcomes Associated with Warfarin Versus Apixaban in the Treatment of Patients with Venous Thromboembolism in a Large U.S. Commercial Claims Database.
    Guo JD; Rajpura J; Hlavacek P; Keshishian A; Sah J; Delinger R; Mu Q; Mardekian J; Russ C; Okano GJ; Rosenblatt L
    J Manag Care Spec Pharm; 2020 Aug; 26(8):1017-1026. PubMed ID: 32452277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A systematic review of direct oral anticoagulant use in chronic kidney disease and dialysis patients with atrial fibrillation.
    Feldberg J; Patel P; Farrell A; Sivarajahkumar S; Cameron K; Ma J; Battistella M
    Nephrol Dial Transplant; 2019 Feb; 34(2):265-277. PubMed ID: 29509922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of oral anticoagulants for the extended treatment of venous thromboembolism using a mixed-treatment comparison, meta-analytic approach.
    Rollins BM; Silva MA; Donovan JL; Kanaan AO
    Clin Ther; 2014 Oct; 36(10):1454-64.e3. PubMed ID: 25092394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.